Company: MDCXW
Filing Date: 2025-09-19
Form Type: DRS
Source: 0001062993-25-015719
Chunk: 207

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-19
Form: DRS
Chunk 207
---
,340,000 Private Warrants. Each Private Warrant is exercisable for one common share at an exercise price of $3.75 per share. The Private Warrants were issued on July 14, 2025 in connection with the Warrant Inducement Agreement and are exercisable at any time up for a period of five years following the date of issuance, expiring on or prior to 5:00 pm ET on July 15, 2030. In addition, one of the series of Private Warrants contains a right for the Company to force the Holder to exercise such New Warrants, subject to certain conditions described in the New Warrants, in the event that the average VWAP (as defined in the Private Warrants) of the Common Shares during any ten (10) Trading Day (as defined in the Private Warrants) period shall equal or exceed $10.00.

The number of Private Warrants outstanding, and the exercise price of those securities, will be adjusted proportionately in the event of a consolidation or share split of our common shares, a recapitalization or reclassification of our common shares, payment of dividends or distributions in common shares to our common share holders, or similar transactions. In the event that the Company effects a rights offering to its common share holders or a pro rata distribution of its assets among its common share holders, then the holders of the Private Warrants will have the right to participate in such distribution and rights offering to the extent of their pro rata share of the Company's outstanding common shares assuming they owned the number of common shares issuable upon the exercise of their Private Warrants. In the event of a "Fundamental Transaction" by the Company, such as a merger or consolidation of it with another company, the sale or other disposition of all or substantially all of the Company's assets in one or a series of related transactions, a purchase offer, tender offer or exchange offer, or any reclassification, reorganization or recapitalization of the common shares, then the Private Warrant holders will have the right to receive, for each common share issuable upon the exercise of an Private Warrant, at the option of the holder, the number of common shares of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration payable as a result of the Fundamental Transaction, that would have been issued or conveyed to the Private Warrant holder had the Private Warrant holder exercised the Private Warrant immediately preceding the closing of the Fundamental Transaction